Evidence of skin field cancerization

Field Cancerization: Basic Science and Clinical Applications

Volumn , Issue , 2011, Pages 317-370

  Carlson, J Andrew ^a   Murphy, Michael ^b   Slominski, Andrzej ^c   Wilson, Vincent L ^d  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79958856460     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (296)

1. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J. Am. Acad. Dermatol. 1994 May;30(5 Pt 1):774-8.
2. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br. J. Dermatol. 2002 Apr;146 Suppl 61:1-6.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 2009 Jul-Aug;59(4):225-49.
4. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch. Dermatol. 2010 Mar;146(3):283-7.
5. Stern RS. Prevalence of a history of skin cancer in 2007: results of an incidence-based model. Arch. Dermatol. 2010 Mar;146(3):279-82.
6. Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight. Adv. Exp. Med. Biol. 2008;624:89-103.
7. Carlson JA, Ross JS, Slominski AJ. New techniques in dermatopathology that help to diagnose and prognosticate melanoma. Clin. Dermatol. 2009 Jan-Feb;27(1):75-102.
8. Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J. Clin. 2000 Jul-Aug;50(4):215-36; quiz 37-40.
9. Beddingfield FC, 3rd. The melanoma epidemic: res ipsa loquitur. Oncologist. 2003;8(5):459-65.
10. Eide MJ, Krajenta R, Johnson D, Long JJ, Jacobsen G, Asgari MM, et al. Identification of patients with nonmelanoma skin cancer using health maintenance organization claims data. Am. J. Epidemiol. 2010 Jan 1;171(1):123-8.
11. Desmond RA, Soong SJ. Epidemiology of malignant melanoma. Surg. Clin. North Am. 2003 Feb;83(1):1-29.
12. Thompson JF, Morton DL, Kroon BBE. Textbook of Melanoma. London: Martin Dunitz; 2004.
13. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005 Feb 19;365(9460):687-701.
14. Housman TS, Feldman SR, Williford PM, Fleischer AB, Jr., Goldman ND, Acostamadiedo JM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J. Am. Acad. Dermatol. 2003 Mar;48(3):425-9.
15. Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J. Am. Acad. Dermatol. 2006 Sep;55(3):490-500.
16. Seidler AM, Pennie ML, Veledar E, Culler SD, Chen SC. Economic Burden of Melanoma in the Elderly Population: Population-Based Analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare Data. Arch. Dermatol. 2010 Mar;146(3):249-56.
17. Martinez JC, Otley CC. Megasession: excision of numerous skin cancers in a single session. Dermatol Surg. 2005 Jul;31(7 Pt 1):757-61; discussion 61-2.
18. Schinstine M, Goldman GD. Risk of synchronous and metachronous second nonmelanoma skin cancer when referred for Mohs micrographic surgery. J. Am. Acad Dermatol. 2001 Mar;44(3):497-9.
19. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J. Am. Acad. Dermatol. 2002 Jul;47(1):1-17; quiz 8-20.
20. Veness MJ, Quinn DI, Ong CS, Keogh AM, Macdonald PS, Cooper SG, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer. 1999 Apr 15;85(8):1758-64.
21. Spanogle JP, Clarke CA, Aroner S, Swetter SM. Risk of second primary malignancies following cutaneous melanoma diagnosis: A population-based study. J. Am. Acad. Dermatol. 2010 Mar 9.
22. Bradford PT, Freedman DM, Goldstein AM, Tucker MA. Increased risk of second primary cancers after a diagnosis of melanoma. Arch. Dermatol. 2010 Mar;146(3):265-72.
23. Tessari G, Naldi L, Boschiero L, Nacchia F, Fior F, Forni A, et al. Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study. Arch Dermatol. 2010 Mar;146(3):294-9.
24. Cantwell MM, Murray LJ, Catney D, Donnelly D, Autier P, Boniol M, et al. Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland. Br. J. Cancer. 2009 Jan 13;100(1):174-7.
25. McCaul KA, Fritschi L, Baade P, Coory M. The incidence of second primary invasive melanoma in Queensland, 1982-2003. Cancer Causes Control. 2008 Jun;19(5):451-8.
26. Maitra SK, Gallo H, Rowland-Payne C, Robinson D, Moller H. Second primary cancers in patients with squamous cell carcinoma of the skin. Br. J. Cancer. 2005 Feb 14;92(3):570-1.
27. Crocetti E, Carli P. Risk of second primary cancers, other than melanoma, in an Italian population-based cohort of cutaneous malignant melanoma patients. Eur. J. Cancer Prev. 2004 Feb;13(1):33-7.
28. Savoia P, Quaglino P, Verrone A, Bernengo MG. Multiple primary melanomas: analysis of 49 cases. Melanoma Res. 1998 Aug;8(4):361-6.
29. Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer. 2003 Feb 1;97(3):639-43.
30. Wassberg C, Thorn M, Yuen J, Ringborg U, Hakulinen T. Second primary cancers in patients with squamous cell carcinoma of the skin: a population-based study in Sweden. Int. J. Cancer. 1999 Feb 9;80(4):511-5.
31. Bangash SJ, Green WH, Dolson DJ, Cognetta AB, Jr. Eruptive postoperative squamous cell carcinomas exhibiting a pathergy-like reaction around surgical wound sites. J. Am. Acad Dermatol. 2009 Nov;61(5):892-7.
32. Nugent Z, Demers AA, Wiseman MC, Mihalcioiu C, Kliewer EV. Risk of second primary cancer and death following a diagnosis of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2584-90.
33. Rosenberg CA, Greenland P, Khandekar J, Loar A, Ascensao J, Lopez AM. Association of nonmelanoma skin cancer with second malignancy. Cancer. 2004 Jan 1;100(1):130-8.
34. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953 Sep;6(5):963-8.
35. Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL. Clinical implications and utility of field cancerization. Cancer Cell Int. 2007;7:2.
36. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70.
37. Tapp RA, Feng J, Jones JW, Carlson JA, Wilson VL. Single base instability is promoted in vulvar lichen sclerosus. J. Invest Dermatol. 2007 Nov;127(11):2563-76.
38. Backvall H, Wolf O, Hermelin H, Weitzberg E, Ponten F. The density of epidermal p53 clones is higher adjacent to squamous cell carcinoma in comparison with basal cell carcinoma. Br.J. Dermatol. 2004 Feb;150(2):259-66.
39. North JP, Kageshita T, Pinkel D, LeBoit PE, Bastian BC. Distribution and significance of occult intraepidermal tumor cells surrounding primary melanoma. J. Invest Dermatol. 2008 Aug;128(8):2024-30.
40. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003 Apr 15;63(8):1727-30.
41. Hittelman WN. Genetic instability in epithelial tissues at risk for cancer. Ann. N Y Acad Sci. 2001 Dec;952:1-12.
42. Bielas JH, Loeb LA. Mutator phenotype in cancer: timing and perspectives. Environ. Mol. Mutagen. 2005 Mar-Apr;45(2-3):206-13.
43. Nowell PC. Tumor progression: a brief historical perspective. Semin. Cancer Biol. 2002 Aug;12(4):261-6.
44. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability--an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 2010 Mar;11(3):220-8.
45. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010 Jan 14;463(7278):191-6.
46. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2009 Apr 1;101(7):452-74.
47. Loeb LA, Bielas JH, Beckman RA. Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 2008 May 15;68(10):3551-7; discussion 7.
48. Kaur P, Mulvaney M, Carlson JA. Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis. Am. J. Dermatopathol. 2006 Aug;28(4):293-307.
49. Carlson JA, Healy K, Tran TA, Malfetano J, Wilson VL, Rohwedder A, et al. Chromosome 17 aneusomy detected by fluorescence in situ hybridization in vulvar squamous cell carcinomas and synchronous vulvar skin. Am. J. Pathol. 2000 Sep;157(3):973-83.
50. Carlson JA, Amin S, Malfetano J, Tien AT, Selkin B, Hou J, et al. Concordant p53 and mdm-2 protein expression in vulvar squamous cell carcinoma and adjacent lichen sclerosus. Appl. Immunohistochem Mol. Morphol. 2001 Jun;9(2):150-63.
51. Padilla RS, Sebastian S, Jiang Z, Nindl I, Larson R. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch. Dermatol. 2010 Mar;146(3):288-93.
52. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer. 1954 Mar;8(1):1-12.
53. Dore JF, Pedeux R, Boniol M, Chignol MC, Autier P. Intermediate-effect biomarkers in prevention of skin cancer. IARC Sci Publ. 2001;154:81-91.
54. Ashton KJ, Carless MA, Griffiths LR. Cytogenetic alterations in nonmelanoma skin cancer: a review. Genes Chromosomes Cancer. 2005 Jul;43(3):239-48.
55. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis. 2005 Oct;26(10):1657-67.
56. Blokx WA, van Dijk MC, Ruiter DJ. Molecular cytogenetics of cutaneous melanocytic lesions -diagnostic, prognostic and therapeutic aspects. Histopathology. 2010 Jan;56(1):121-32.
57. Dadzie OE, Yang S, Emley A, Keady M, Bhawan J, Mahalingam M. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis. Br. J. Dermatol. 2009 Feb;160(2):368-75.
58. Rubin H. Saturation density of skin fibroblasts as a quantitative screen for human cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2366-72.
59. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010 Jan 14;463(7278):184-90.
60. Boland CR, Ricciardiello L. How many mutations does it take to make a tumor? Proc. Natl. Acad. Sci. USA. 1999 Dec 21;96(26):14675-7.
61. Benitah SA. Epidermal stem cells in skin homeostasis and cutaneous carcinomas. Clin. Transl Oncol. 2007 Dec;9(12):760-6.
62. Lau K, Paus R, Tiede S, Day P, Bayat A. Exploring the role of stem cells in cutaneous wound healing. Exp. Dermatol. 2009 Nov;18(11):921-33.
63. LeBleu VS, Macdonald B, Kalluri R. Structure and function of basement membranes. Exp Biol. Med. (Maywood). 2007 Oct;232(9):1121-9.
64. Iozzo RV. Basement membrane proteoglycans: from cellar to ceiling. Nat. Rev. Mol. Cell Biol. 2005 Aug;6(8):646-56.
65. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009 Nov 19;462(7271):315-22.
66. Broske AM, Vockentanz L, Kharazi S, Huska MR, Mancini E, Scheller M, et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nature genetics. 2009 Nov;41(11):1207-15.
67. Harley CB. Telomerase and cancer therapeutics. Nat. Rev. Cancer. 2008 Mar;8(3):167-79.
68. Parkinson EK. Epidermal keratinocyte stem cells: their maintenance and regulation. Seminars in cell biology. 1992 Dec;3(6):435-44.
69. Potten CS, Booth C. Keratinocyte stem cells: a commentary. J. Invest Dermatol. 2002 Oct;119(4):888-99.
70. Ghazizadeh S, Taichman LB. Organization of stem cells and their progeny in human epidermis. J. Invest Dermatol. 2005 Feb;124(2):367-72.
71. Lippens S, Hoste E, Vandenabeele P, Agostinis P, Declercq W. Cell death in the skin. Apoptosis. 2009 Apr;14(4):549-69.
72. Lu S, Slominski A, Yang S-E, Sheehan C, Ross J, Carlson JA. The correlation of TRPM1 (Melastatin) mRNA expression with microphthalmia-associated transcription factor (MITF) and other melanogenesis-related proteins in normal and pathological skin, hair follicles and melanocytic nevi. J. Cutan Pathol. 2010;37(Suppl. 1):26-40.
73. Gleason BC, Crum CP, Murphy GF. Expression patterns of MITF during human cutaneous embryogenesis: evidence for bulge epithelial expression and persistence of dermal melanoblasts. J. Cutan. Pathol. 2008;35:615-22.
74. Jones PH, Harper S, Watt FM. Stem cell patterning and fate in human epidermis. Cell. 1995 Jan 13;80(1):83-93.
75. Li A, Simmons PJ, Kaur P. Identification and isolation of candidate human keratinocyte stem cells based on cell surface phenotype. Proc. Natl. Acad. Sci. USA. 1998 Mar 31;95(7):3902-7.
76. Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bondanza S, et al. p63 identifies keratinocyte stem cells. Proc. Natl. Acad. Sci. USA. 2001 Mar 13;98(6):3156-61.
77. Yu Y, Flint A, Dvorin EL, Bischoff J. AC133-2, a novel isoform of human AC133 stem cell antigen. J. Biol. Chem. 2002 Jun 7;277(23):20711-6.
78. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004 Oct;84(4):1155-228.
79. Slominski A, Wortsman J, Plonka PM, Schallreuter KU, Paus R, Tobin DJ. Hair follicle pigmentation. J. Invest Dermatol. 2005 Jan;124(1):13-21.
80. White RM, Zon LI. Melanocytes in development, regeneration, and cancer. Cell Stem Cell. 2008 Sep 11;3(3):242-52.
81. Grichnik JM. Melanoma, nevogenesis, and stem cell biology. J. Invest Dermatol. 2008 Oct;128(10):2365-80.
82. Cramer SF. Stem cells for epidermal melanocytes--a challenge for students of dermatopathology. Am. J. Dermatopathol. 2009 Jun;31(4):331-41.
83. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N. Engl J. Med. 2005 Nov 17;353(20):2135-47.
84. Zalaudek I, Marghoob AA, Scope A, Leinweber B, Ferrara G, Hofmann-Wellenhof R, et al. Three roots of melanoma. Arch. Dermatol. 2008 Oct;144(10):1375-9.
85. Cairns J. Somatic stem cells and the kinetics of mutagenesis and carcinogenesis. Proc. Natl. Acad. Sci. USA. 2002 Aug 6;99(16):10567-70.
86. Backvall H, Asplund A, Gustafsson A, Sivertsson A, Lundeberg J, Ponten F. Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma. Mutat Res. 2005 Apr 1;571(1-2):65-79.
87. Ren Z, Ponten F, Nister M, Ponten J. Reconstruction of the two-dimensional distribution of p53 positive patches in sun-exposed skin morphologically normal skin. Inter J. Oncol. 1997;11:111-5.
88. Brash DE, Ponten J. Skin precancer. Cancer Surv. 1998;32:69-113.
89. Berg RJ, van Kranen HJ, Rebel HG, de Vries A, van Vloten WA, Van Kreijl CF, et al. Early p53 alterations in mouse skin carcinogenesis by UVB radiation: immunohistochemical detection of mutant p53 protein in clusters of preneoplastic epidermal cells. Proc. Natl. Acad. Sci. USA. 1996 Jan 9;93(1):274-8.
90. Asplund A, Guo Z, Hu X, Wassberg C, Ponten F. Mosaic pattern of maternal and paternal keratinocyte clones in normal human epidermis revealed by analysis of X-chromosome inactivation. J. Invest Dermatol. 2001 Jul;117(1):128-31.
91. Jonason AS, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc. Natl. Acad. Sci. USA. 1996 Nov 26;93(24):14025-9.
92. Zhang W, Remenyik E, Zelterman D, Brash DE, Wikonkal NM. Escaping the stem cell compartment: sustained UVB exposure allows p53-mutant keratinocytes to colonize adjacent epidermal proliferating units without incurring additional mutations. Proc. Natl. Acad. Sci. USA. 2001 Nov 20;98(24):13948-53.
93. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer. 2006 Dec;6(12):924-35.
94. Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet. 2010 Feb 20;375(9715):673-85.
95. Wood JM, Jimbow K, Boissy RE, Slominski A, Plonka PM, Slawinski J, et al. What's the use of generating melanin? Exp. Dermatol. 1999 Apr;8(2):153-64.
96. Slominski A, Paus R, Schanderdorf D. Melanocytes as sensory and regulatory cells in the epidermis. J. Theor. Biol. 1993;164:103-20.
97. Hoy WE. Nonmelanoma skin carcinoma in Albuquerque, New Mexico: experience of a major health care provider. Cancer. 1996 Jun 15;77(12):2489-95.
98. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000 Dec;136(12):1524-30.
99. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J. Photochem. Photobiol. B. 2001 Oct;63(1-3):8-18.
100. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 2006 Sep 10;24(26):4340-6.
101. Brozyna A, Zbytek B, Granese J, Carlson JA, Ross J, Slominski A. Mechanism of UV-related carcinogenesis and its contribution to nevi/melanoma. Expert. Rev. Dermatol. 2007;2(4):451-69.
102. Lee DA, Miller SJ. Nonmelanoma skin cancer. Facial Plast Surg Clin. North Am. 2009 Aug;17(3):309-24.
103. Carlson JA, Slominski A, Linette GP, Mihm MC, Jr., Ross JS. Biomarkers in melanoma: predisposition, screening and diagnosis. Expert Rev. Mol. Diagn. 2003 Mar;3(2):163-84.
104. Naldi L, Altieri A, Imberti GL, Gallus S, Bosetti C, La Vecchia C. Sun exposure, phenotypic characteristics, and cutaneous malignant melanoma. An analysis according to different clinico-pathological variants and anatomic locations (Italy). Cancer Causes Control. 2005 Oct;16(8):893-9.
105. Andersen WK, Labadie RR, Bhawan J. Histopathology of solar lentigines of the face: a quantitative study. J. Am. Acad. Dermatol. 1997 Mar;36(3 Pt 1):444-7.
106. Kossard S. Atypical lentiginous junctional naevi of the elderly and melanoma. Australas J. Dermatol. 2002 May;43(2):93-101.
107. Mittelbronn MA, Mullins DL, Ramos-Caro FA, Flowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol. 1998 Sep;37(9):677-81.
108. Olson R, Jones DM, Carlson JA. The role of dermatopathology in clinical dermatology. Journal of Malaysian Dermatology. 2007;19(August):5-17.
109. Arumi-Uria M, McNutt NS, Finnerty B. Grading of atypia in nevi: correlation with melanoma risk. Mod Pathol. 2003 Aug;16(8):764-71.
110. Hafner C, Vogt T. Seborrheic keratosis. J. Dtsch Dermatol. Ges. 2008 Aug;6(8):664-77.
111. Carlson JA, Scott D, Wharton J, Sell S. Incidental histopathologic patterns: possible evidence of 'field cancerization' surrounding skin tumors. Am. J. Dermatopathol. 2001 Oct;23(5):494-6.
112. Rohwedder A, Foong H, Tyring SK, Rady P, Carlson JA. Incidental epidermodysplasia verruciformis human papillomavirus infection (EV acanthoma): evidence for 'field cancerization' and a putative cofactor in seborrheic keratosis. J. Cutan Pathol. 2008 Dec;35(12):1151-5.
113. Hutcheson AC, Nietert PJ, Maize JC. Incidental epidermolytic hyperkeratosis and focal acantholytic dyskeratosis in common acquired melanocytic nevi and atypical melanocytic lesions. J. Am. Acad. Dermatol. 2004 Mar;50(3):388-90.
114. Brownstein MH. Acantholytic acanthoma. J. Am. Acad. Dermatol. 1988 Nov;19(5 Pt 1):783-6.
115. Roten SV, Bhawan J. Isolated dyskeratotic acanthoma. A variant of isolated epidermolytic acanthoma. Am. J. Dermatopathol. 1995 Feb;17(1):63-6.
116. Ko CJ, Iftner T, Barr RJ, Binder SW. Changes of epidermodysplasia verruciformis in benign skin lesions: the EV acanthoma. J. Cutan Pathol. 2007 Jan;34(1):44-8.
117. Ko CJ, Barr RJ, Subtil A, McNiff JM. Acantholytic dyskeratotic acanthoma: a variant of a benign keratosis. J. Cutan Pathol. 2008 Mar;35(3):298-301.
118. Harwood CA, Surentheran T, Sasieni P, Proby CM, Bordea C, Leigh IM, et al. Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin. Br. J. Dermatol. 2004 May;150(5):949-57.
119. Bjorn LM. Photobiology: The Science of Life and Light. Second ed. New York: Springer; 2008.
120. Slominski A, Pawelek J. Animals under the sun: effects of ultraviolet radiation on mammalian skin. Clin. Dermatol. 1998 Jul-Aug;16(4):503-15.
121. Runger TM. How different wavelengths of the ultraviolet spectrum contribute to skin carcinogenesis: the role of cellular damage responses. J. Invest Dermatol. 2007 Sep;127(9):2103-5.
122. Agar NS, Halliday GM, Barnetson RS, Ananthaswamy HN, Wheeler M, Jones AM. The basal layer in human squamous tumors harbors more UVA than UVB fingerprint mutations: a role for UVA in human skin carcinogenesis. Proc. Natl. Acad. Sci. USA. 2004 Apr 6;101(14):4954-9.
123. Greinert R. Skin cancer: new markers for better prevention. Pathobiology. 2009;76(2):64-81.
124. Kielbassa C, Roza L, Epe B. Wavelength dependence of oxidative DNA damage induced by UV and visible light. Carcinogenesis. 1997 Apr;18(4):811-6.
125. Abdel-Malek ZA, Kadekaro AL, Swope VB. Stepping up melanocytes to the challenge of UV exposure. Pigment Cell Melanoma Res. 2010 Feb 1.
126. Nordlund JJ. Nonmelanoma skin cancer in vitiligo patients. J. Am. Acad Dermatol. 2009 Dec;61(6):1080-1.
127. Smit NP, van Nieuwpoort FA, Marrot L, Out C, Poorthuis B, van Pelt H, et al. Increased melanogenesis is a risk factor for oxidative DNA damage--study on cultured melanocytes and atypical nevus cells. Photochem Photobiol. 2008 May-Jun;84(3):550-5.
128. Lear JT, Smith AG, Strange RC, Fryer AA. Detoxifying enzyme genotypes and susceptibility to cutaneous malignancy. Br. J. Dermatol. 2000 Jan;142(1):8-15.
129. Wang LE, Li C, Strom SS, Goldberg LH, Brewster A, Guo Z, et al. Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin. Cancer Res. 2007 Nov 1;13(21):6532-9.
130. Steinberg ML, Hubbard K, Utti C, Clas B, Hwang BJ, Hill HZ, et al. Patterns of persistent DNA damage associated with sun exposure and the glutathione S-transferase M1 genotype in melanoma patients. Photochem Photobiol. 2009 Jan-Feb;85(1):379-86.
131. Takahashi Y, Moriwaki S, Sugiyama Y, Endo Y, Yamazaki K, Mori T, et al. Decreased gene expression responsible for post-ultraviolet DNA repair synthesis in aging: a possible mechanism of age-related reduction in DNA repair capacity. J. Invest Dermatol. 2005 Feb;124(2):435-42.
132. Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin. Pharmacol Ther. 2010 Apr;87(4):504-8.
133. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl J. Med. 1986 Dec 25;315(26):1650-9.
134. Cruikshank AH, McConnell EM, Miller DG. Malignancy in scars, chronic ulcers and sinuses. J Clin Pathol. 1963;16:573-80.
135. Kowal-Vern A, Criswell BK. Burn scar neoplasms: a literature review and statistical analysis. Burns. 2005 Jun;31(4):403-13.
136. Carlson JA, Ambros R, Malfetano J, Ross J, Grabowski R, Lamb P, et al. Vulvar lichen sclerosus and squamous cell carcinoma: a cohort, case control, and investigational study with historical perspective; implications for chronic inflammation and sclerosis in the development of neoplasia. Hum Pathol. 1998 Sep;29(9):932-48.
137. Carli P, De Magnis A, Mannone F, Botti E, Taddei G, Cattaneo A. Vulvar carcinoma associated with lichen sclerosus. Experience at the Florence, Italy, Vulvar Clinic. J. Reprod Med. 2003 May;48(5):313-8.
138. Carlson JA, Grabowski R, Chichester P, Paunovich E, Malfetano J. Comparative immunophenotypic study of lichen sclerosus: epidermotropic CD57+ lymphocytes are numerous--implications for pathogenesis. Am. J. Dermatopathol. 2000 Feb;22(1):7-16.
139. Sander CS, Ali I, Dean D, Thiele JJ, Wojnarowska F. Oxidative stress is implicated in the pathogenesis of lichen sclerosus. Br. J. Dermatol. 2004 Sep;151(3):627-35.
140. Smoller BR, Krueger J, McNutt NS, Hsu A. " Activated" keratinocyte phenotype is unifying feature in conditions which predispose to squamous cell carcinoma of the skin. Mod Pathol. 1990;3(2):171-5.
141. Antonsson A, Erfurt C, Hazard K, Holmgren V, Simon M, Kataoka A, et al. Prevalence and type spectrum of human papillomaviruses in healthy skin samples collected in three continents. J. Gen. Virol. 2003 Jul;84(Pt 7):1881-6.
142. Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J. Virol. 2000 Dec;74(24):11636-41.
143. Antonsson A, Karanfilovska S, Lindqvist PG, Hansson BG. General acquisition of human papillomavirus infections of skin occurs in early infancy. J. Clin. Microbiol. 2003 Jun;41(6):2509-14.
144. Chan SY, Delius H, Halpern AL, Bernard HU. Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J. Virol. 1995;69(5):3074-83.
145. Chan JK, Monk BJ, Brewer C, Keefe KA, Osann K, McMeekin S, et al. HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3. Br. J. Cancer. 2003 Sep 15;89(6):1062-6.
146. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J. Infect Dis. 1999 Nov;180(5):1415-23.
147. Koutsky L. Epidemiology of genital human papillomavirus infection. Am. J. Med. 1997;102(5A):3-8.
148. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007 Feb 28;297(8):813-9.
149. Orth G. Human papillomaviruses associated with epidermodysplasia verruciformis in non-melanoma skin cancers: guilty or innocent? J. Invest Dermatol. 2005 Jul;125(1):xii-xiii.
150. Caldeira S, Zehbe I, Accardi R, Malanchi I, Dong W, Giarre M, et al. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J. Virol. 2003 Feb;77(3):2195-206.
151. Plasmeijer EI, Neale RE, de Koning MN, Quint WG, McBride P, Feltkamp MC, et al. Persistence of betapapillomavirus infections as a risk factor for actinic keratoses, precursor to cutaneous squamous cell carcinoma. Cancer Res. 2009 Dec 1;69(23):8926-31.
152. Plasmeijer EI, Neale RE, Buettner PG, de Koning MN, Ter Schegget J, Quint WG, et al. Betapapillomavirus infection profiles in tissue sets from cutaneous squamous cell-carcinoma patients. Int. J. Cancer. 2009 Oct 23;126(11):2614-21.
153. Zhang HG, Grizzle WE. Aging, immunity, and tumor susceptibility. Immunol Allergy Clin. North Am. 2003 Feb;23(1):83-102, vi.
154. Wilson RE, Hager EB, Hampers CL, Corson JM, Merrill JP, Murray JE. Immunologic rejection of human cancer transplanted with a renal allograft. N. Engl. J. Med. 1968 Feb 29;278(9):479-83.
155. Franceschi S, Dal Maso L, Arniani S, Crosignani P, Vercelli M, Simonato L, et al. Risk of cancer other than Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br. J. Cancer. 1998 Oct;78(7):966-70.
156. Oram Y, Orengo I, Griego RD, Rosen T, Thornby J. Histologic patterns of basal cell carcinoma based upon patient immunostatus. Dermatol Surg. 1995 Jul;21(7):611-4.
157. Mehrany K, Byrd DR, Roenigk RK, Weenig RH, Phillips PK, Nguyen TH, et al. Lymphocytic infiltrates and subclinical epithelial tumor extension in patients with chronic leukemia and solid-organ transplantation. Dermatol Surg. 2003 Feb;29(2):129-34.
158. Weimar VM, Ceilley RI, Goeken JA. Aggressive biologic behavior of basal-and squamous-cell cancers in patients with chronic lymphocytic leukemia or chronic lymphocytic lymphoma. J Derm Surg Oncol. 1979 Aug;5(8):609-14.
159. Casabonne D, Lally A, Mitchell L, Michael KM, Waterboer T, Pawlita M, et al. A case-control study of cutaneous squamous cell carcinoma among Caucasian organ transplant recipients: the role of antibodies against human papillomavirus and other risk factors. Int. J. Cancer. 2009 Oct 15;125(8):1935-45.
160. Stockfleth E, Nindl I, Sterry W, Ulrich C, Schmook T, Meyer T. Human papillomaviruses in transplant-associated skin cancers. Dermatol. Surg. 2004 May;30(4 Pt 2):604-9.
161. Kripke ML. Ultraviolet radiation and immunology: something new under the sun--presidential address. Cancer Res. 1994 Dec 1;54(23):6102-5.
162. Slominski A. A nervous breakdown in the skin: stress and the epidermal barrier. J. Clin. Invest. 2007 Nov;117(11):3166-9.
163. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr. Rev. 2000 Oct;21(5):457-87.
164. Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol. Rev. 2000 Jul;80(3):979-1020.
165. Schwarz T. Ultraviolet radiation-induced tolerance. Allergy. 1999 Dec;54(12):1252-61.
166. Schwarz A, Maeda A, Wild MK, Kernebeck K, Gross N, Aragane Y, et al. Ultraviolet radiation-induced regulatory T cells not only inhibit the induction but can suppress the effector phase of contact hypersensitivity. J. Immunol. 2004 Jan 15;172(2):1036-43.
167. Ruocco E, Puca RV, Brunetti G, Schwartz RA, Ruocco V. Lymphedematous areas: privileged sites for tumors, infections, and immune disorders. Int J Dermatol 2007 Jun;46(6):662.
168. Benson PM, Pessoa CM, Lupton GP, Winton GB. Basal cell carcinomas arising in chronic lymphedema. J. Dermatol. Surg. Oncol. 1988 Jul;14(7):781-3.
169. Kajiya K, Kunstfeld R, Detmar M, Chung JH. Reduction of lymphatic vessels in photodamaged human skin. J. Dermatol. Sci. 2007 Sep;47(3):241-3.
170. Acker DW, Helwig EB. Rhinophyma with carcinoma. Arch. Dermatol. 1967 Mar;95(3):250-4.
171. Meyskens FL, Jr., Farmer PJ, Yang S, Anton-Culver H. New perspectives on melanoma pathogenesis and chemoprevention. Recent Results Cancer Res. 2007;174:191-5.
172. Slominski A, Zbytek B, Slominski R. Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells. Int. J. Cancer. 2009 Mar 15;124(6):1470-7.
173. Urbanska K, Romanowska-Dixon B, Elas M, Pajak S, Paziewski E, Bryk J, et al. Experimental ruthenium plaque therapy of amelanotic and melanotic melanomas in the hamster eye. Melanoma Res. 2000 Feb;10(1):26-35.
174. Slominski A, Paus R. Towards defining receptors for L-tyrosine and L-dopa. Mol. Cell Endocrinol. 1994 Mar;99(2):C7-11.
175. Slominski A, Paus R, Mihm M. Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis. Anticancer Res. 1998;18:3709-16.
176. Fruehauf JP, Meyskens FL, Jr. Reactive oxygen species: a breath of life or death? Clin Cancer Res. 2007 Feb 1;13(3):789-94.
177. Slominski A. Neuroendocrine activity of the melanocyte. Exp. Dermatol. 2009 Sep;18(9):760-3.
178. Hussein MR, Wood GS. Microsatellite instability and its relevance to cutaneous tumorigenesis. J. Cutan Pathol. 2002 May;29(5):257-67.
179. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol. 1999 Dec;9(12):M57-60.
180. Ushijima T. Epigenetic field for cancerization. J. Biochem. Mol. Biol. 2007 Mar 31;40(2):142-50.
181. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998 Dec 17;396(6712):643-9.
182. Duesberg PH. Are cancers dependent on oncogenes or on aneuploidy? Cancer Genet Cytogenet. 2003 May;143(1):89-91.
183. Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak MA. Can chromosomal instability initiate tumorigenesis? Semin. Cancer Biol. 2005 Feb;15(1):43-9.
184. Kanellou P, Zaravinos A, Zioga M, Stratigos A, Baritaki S, Soufla G, et al. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis. Cancer Lett. 2008 Jun 8;264(1):145-61.
185. Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum. Mutat. 2007 Feb 12.
186. Sabatino M, Zhao Y, Voiculescu S, Monaco A, Robbins P, Karai L, et al. Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res. 2008 Jan 1;68(1):122-31.
187. Beckman RA, Loeb LA. Efficiency of carcinogenesis with and without a mutator mutation. Proc. Natl. Acad Sci USA. 2006 Sep 19;103(38):14140-5.
188. Blanquet V, Turleau C, Gross-Morand MS, Senamaud-Beaufort C, Doz F, Besmond C. Spectrum of germline mutations in the RB1 gene: a study of 232 patients with hereditary and non hereditary retinoblastoma. Hum. Mol. Genet. 1995 Mar;4(3):383-8.
189. Hussain SP, Harris CC. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 1998 Sep 15;58(18):4023-37.
190. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759-67.
191. Wilson VL. Detecting rare mutations associated with cancer risk. Am. J. Pharmacogenomics. 2001;1(4):283-93.
192. Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, et al. The Human Gene Mutation Database: 2008 update. Genome Med. 2009 Jan 22;1(1):13.
193. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007 Jun;28(6):622-9.
194. Kumar R, Angelini S, Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene. 2003 Dec 18;22(58):9217-24.
195. Nakazawa H, English D, Randell PL, Nakazawa K, Martel N, Armstrong BK, et al. UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc. Natl. Acad. Sci. USA. 1994 Jan 4;91(1):360-4.
196. Kanjilal S, Strom SS, Clayman GL, Weber RS, el-Naggar AK, Kapur V, et al. p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res. 1995 Aug 15;55(16):3604-9.
197. Ren ZP, Ahmadian A, Ponten F, Nister M, Berg C, Lundeberg J, et al. Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin. Am. J. Pathol. 1997 May;150(5):1791-803.
198. Ouhtit A, Ueda M, Nakazawa H, Ichihashi M, Dumaz N, Sarasin A, et al. Quantitative detection of ultraviolet-specific p53 mutations in normal skin from Japanese patients. Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):433-8.
199. Williams C, Ponten F, Ahmadian A, Ren ZP, Ling G, Rollman O, et al. Clones of normal keratinocytes and a variety of simultaneously present epidermal neoplastic lesions contain a multitude of p53 gene mutations in a xeroderma pigmentosum patient. Cancer Res. 1998 Jun 1;58(11):2449-55.
200. Ling G, Persson A, Berne B, Uhlen M, Lundeberg J, Ponten F. Persistent p53 mutations in single cells from normal human skin. Am. J Pathol. 2001 Oct;159(4):1247-53.
201. Backvall H, Stromberg S, Gustafsson A, Asplund A, Sivertsson A, Lundeberg J, et al. Mutation spectra of epidermal p53 clones adjacent to basal cell carcinoma and squamous cell carcinoma. Exp. Dermatol. 2004 Oct;13(10):643-50.
202. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science. 1994 May 27;264(5163):1317-9.
203. Wilson VL, Yin X, Thompson B, Wade KR, Watkins JP, Wei Q, et al. Oncogenic base substitution mutations in circulating leukocytes of normal individuals. Cancer Res. 2000 Apr 1;60(7):1830-4.
204. Eshaghian A, Vleugels RA, Canter JA, McDonald MA, Stasko T, Sligh JE. Mitochondrial DNA deletions serve as biomarkers of aging in the skin, but are typically absent in nonmelanoma skin cancers. J. Invest Dermatol. 2006 Feb;126(2):336-44.
205. Hubbard K, Steinberg ML, Hill H, Orlow I. Mitochondrial DNA deletions in skin from melanoma patients. Ethn. Dis. 2008 Spring;18(2 Suppl 2):S2-38-43.
206. Giglia-Mari G, Sarasin A. TP53 mutations in human skin cancers. Hum Mutat. 2003 Mar;21(3):217-28.
207. Urano Y, Asano T, Yoshimoto K, Iwahana H, Kubo Y, Kato S, et al. Frequent p53 accumulation in the chronically sun-exposed epidermis and clonal expansion of p53 mutant cells in the epidermis adjacent to basal cell carcinoma. J. Invest Dermatol. 1995 Jun;104(6):928-32.
208. Einspahr J, Alberts DS, Aickin M, Welch K, Bozzo P, Grogan T, et al. Expression of p53 protein in actinic keratosis, adjacent, normal-appearing, and non-sun-exposed human skin. Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):583-7.
209. Liang SB, Ohtsuki Y, Furihata M, Takeuchi T, Iwata J, Chen BK, et al. Sun-exposure-and aging-dependent p53 protein accumulation results in growth advantage for tumour cells in carcinogenesis of nonmelanocytic skin cancer. Virchows Arch. 1999 Mar;434(3):193-9.
210. Tabata H, Nagano T, Ray AJ, Flanagan N, Birch-MacHin MA, Rees JL. Low frequency of genetic change in p53 immunopositive clones in human epidermis. J. Invest Dermatol. 1999 Dec;113(6):972-6.
211. Hudson AR, Antley CM, Kohler S, Smoller BR. Increased p53 staining in normal skin of posttransplant, immunocompromised patients and implications for carcinogenesis. Am. J. Dermatopathol. 1999 Oct;21(5):442-5.
212. Mabruk MJ, Toh LK, Murphy M, Leader M, Kay E, Murphy GM. Investigation of the effect of UV irradiation on DNA damage: comparison between skin cancer patients and normal volunteers. J. Cutan Pathol. 2009 Jul;36(7):760-5.
213. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, et al. Mutations of mitotic checkpoint genes in human cancers. Nature. 1998 Mar 19;392(6673):300-3.
214. Lengauer C. Aneuploidy and genetic instability in cancer. Semin. Cancer Biol. 2005 Feb;15(1):1.
215. Silva AG, Graves HA, Guffei A, Ricca TI, Mortara RA, Jasiulionis MG, et al. Telomere-centromere-driven genomic instability contributes to karyotype evolution in a mouse model of melanoma. Neoplasia. 2010 Jan;12(1):11-9.
216. Fabarius A, Hehlmann R, Duesberg PH. Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy. Cancer Genet Cytogenet. 2003 May;143(1):59-72.
217. Quinn AG, Sikkink S, Rees JL. Basal cell carcinomas and squamous cell carcinomas of human skin show distinct patterns of chromosome loss. Cancer Res. 1994 Sep 1;54(17):4756-9.
218. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998 May 15;58(10):2170-5.
219. Carless MA, Griffiths LR. Cytogenetics of melanoma and nonmelanoma skin cancer. Adv. Exp. Med. Biol. 2008;624:227-40.
220. Heaphy CM, Bisoffi M, Fordyce CA, Haaland CM, Hines WC, Joste NE, et al. Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int. J. Cancer. 2006 Jul 1;119(1):108-16.
221. Ahmadian A, Ren ZP, Williams C, Ponten F, Odeberg J, Ponten J, et al. Genetic instability in the 9q22.3 region is a late event in the development of squamous cell carcinoma. Oncogene. 1998 Oct 8;17(14):1837-43.
222. Kushida Y, Miki H, Ohmori M. Loss of heterozygosity in actinic keratosis, squamous cell carcinoma and sun-exposed normal-appearing skin in Japanese: difference between Japanese and Caucasians. Cancer Lett. 1999 Jun 1;140(1-2):169-75.
223. Pashaei S, Li L, Zhang H, Spencer HJ, Schichman SA, Fan CY, et al. Concordant loss of heterozygosity of DNA repair gene, hOGG1, in melanoma in situ and atypical melanocytic hyperplasia. J. Cutan. Pathol. 2008 Jun;35(6):525-31.
224. Krouse RS, Alberts DS, Prasad AR, Yozwiak M, Bartels HG, Liu Y, et al. Progression of skin lesions from normal skin to squamous cell carcinoma. Anal. Quant Cytol. Histol. 2009 Feb;31(1):17-25.
225. Cremer T, Cremer C. Chromosome territories, nuclear architecture and gene regulation in mammalian cells. Nat. Rev. Genet. 2001 Apr;2(4):292-301.
226. Ranger-Moore J, Bartels PH, Bozzo P, Einspahr J, Liu Y, Saboda K, et al. Karyometric analysis of actinic damage in unexposed and sun-exposed skin and in actinic keratoses in untreated individuals. Anal. Quant Cytol. Histol. 2004 Jun;26(3):155-65.
227. Bartels PH, Krouse RS, Prasad AR, Yozwiak M, Liu Y, Bartels HG, et al. Actinic damage in histopathologically normal skin. Anal Quant Cytol Histol. 2008 Dec;30(6):316-22.
228. Carpenter PM, Linden KG, McLaren CE, Li KT, Arain S, Barr RJ, et al. Nuclear morphometry and molecular biomarkers of actinic keratosis, sun-damaged, and nonexposed skin. Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):1996-2002.
229. Udart M, Utikal J, Krahn GM, Peter RU. Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia. 2001 May-Jun;3(3):245-54.
230. Bastian BC, Kashani-Sabet M, Hamm H, Godfrey T, Moore DH, 2nd, Brocker EB, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 2000 Apr 1;60(7):1968-73.
231. Nakamura K, Izumiyama-Shimomura N, Sawabe M, Arai T, Aoyagi Y, Fujiwara M, et al. Comparative analysis of telomere lengths and erosion with age in human epidermis and lingual epithelium. J. Invest Dermatol. 2002 Nov;119(5):1014-9.
232. Wainwright LJ, Middleton PG, Rees JL. Changes in mean telomere length in basal cell carcinomas of the skin. Genes Chromosomes Cancer. 1995 Jan;12(1):45-9.
233. Hussein MR, Wood GS. Microsatellite instability in human melanocytic skin tumors: an incidental finding or a pathogenetic mechanism? J. Cutan Pathol. 2002 Jan;29(1):1-4.
234. Thibodeau SN, French AJ, Roche PC, Cunningham JM, Tester DJ, Lindor NM, et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res. 1996 Nov 1;56(21):4836-40.
235. Mangold E, Pagenstecher C, Leister M, Mathiak M, Rutten A, Friedl W, et al. A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome. J. Med. Genet. 2004 Jul;41(7):567-72.
236. Abbas O, Mahalingam M. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm. J. Cutan Pathol. 2009 Jun;36(6):613-9.
237. Morales-Burgos A, Sanchez JL, Figueroa LD, De Jesus-Monge WE, Cruz-Correa MR, Gonzalez-Keelan C, et al. MSH-2 and MLH-1 protein expression in Muir Torre syndrome-related and sporadic sebaceous neoplasms. P R Health Sci J. 2008 Dec;27(4):322-7.
238. Ponti G, Losi L, Pellacani G, Wannesson L, Cesinaro AM, Venesio T, et al. Malignant melanoma in patients with hereditary nonpolyposis colorectal cancer. Br. J. Dermatol. 2008 Jul;159(1):162-8.
239. Saetta AA, Aroni K, Stamatelli A, Lazaris AC, Patsouris E. Expression of mismatch repair enzymes, hMLH1 and hMSH2 is not associated with microsatellite instability and P53 protein accumulation in basal cell carcinoma. Arch. Dermatol Res. 2005 Sep;297(3):99-107.
240. Young LC, Listgarten J, Trotter MJ, Andrew SE, Tron VA. Evidence that dysregulated DNA mismatch repair characterizes human nonmelanoma skin cancer. Br. J. Dermatol. 2008 Jan;158(1):59-69.
241. Uribe P, Wistuba, II, Gonzalez S. Allelotyping, microsatellite instability, and BRAF mutation analyses in common and atypical melanocytic nevi and primary cutaneous melanomas. Am. J. Dermatopathol. 2009 Jun;31(4):354-63.
242. Hussein MR, Sun M, Tuthill RJ, Roggero E, Monti JA, Sudilovsky EC, et al. Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi. J. Cutan. Pathol. 2001 Aug;28(7):343-50.
243. Howell PM, Jr., Liu S, Ren S, Behlen C, Fodstad O, Riker AI. Epigenetics in human melanoma. Cancer Control. 2009 Jul;16(3):200-18.
244. Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. Nat. Rev Genet. 2009 Nov;10(11):805-11.
245. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010 Jan;31(1):27-36.
246. Bartolomei MS. Genomic imprinting: employing and avoiding epigenetic processes. Genes Dev. 2009 Sep 15;23(18):2124-33.
247. Esteller M. Epigenetics in cancer. N. Engl J. Med. 2008 Mar 13;358(11):1148-59.
248. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. Jan;31(1):27-36.
249. van Doorn R, Gruis NA, Willemze R, van der Velden PA, Tensen CP. Aberrant DNA methylation in cutaneous malignancies. Semin. Oncol. 2005 Oct;32(5):479-87.
250. Liu S, Ren S, Howell P, Fodstad O, Riker AI. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res. 2008 Oct;21(5):545-58.
251. Patino WD, Susa J. Epigenetics of cutaneous melanoma. Adv. Dermatol. 2008;24:59-70.
252. Chiles MC, Ai L, Zuo C, Fan CY, Smoller BR. E-cadherin promoter hypermethylation in preneoplastic and neoplastic skin lesions. Mod Pathol. 2003 Oct;16(10):1014-8.
253. Tyler LN, Ai L, Zuo C, Fan CY, Smoller BR. Analysis of promoter hypermethylation of death-associated protein kinase and p16 tumor suppressor genes in actinic keratoses and squamous cell carcinomas of the skin. Mod. Pathol. 2003 Jul;16(7):660-4.
254. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res. 2003 Apr 1;63(7):1639-43.
255. Behrmann I, Wallner S, Komyod W, Heinrich PC, Schuierer M, Buettner R, et al. Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am. J. Pathol. 2003 Aug;163(2):683-90.
256. Furuta J, Umebayashi Y, Miyamoto K, Kikuchi K, Otsuka F, Sugimura T, et al. Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci. 2004 Dec;95(12):962-8.
257. Miracco C, Pacenti L, Santopietro R, Laurini L, Biagioli M, Luzi P. Evaluation of telomerase activity in cutaneous melanocytic proliferations. Hum. Pathol. 2000 Sep;31(9):1018-21.
258. Taylor RS, Ramirez RD, Ogoshi M, Chaffins M, Piatyszek MA, Shay JW. Detection of telomerase activity in malignant and nonmalignant skin conditions. J. Invest Dermatol. 1996 Apr;106(4):759-65.
259. Ueda M, Ouhtit A, Bito T, Nakazawa K, Lubbe J, Ichihashi M, et al. Evidence for UV-associated activation of telomerase in human skin. Cancer Res. 1997 Feb 1;57(3):370-4.
260. Wu A, Ichihashi M, Ueda M. Correlation of the expression of human telomerase subunits with telomerase activity in normal skin and skin tumors. Cancer. 1999 Nov 15;86(10):2038-44.
261. Fabricius EM, Bezeluk A, Kruse-Boitschenko U, Wildner GP, Klein M. Clinical significance of telomerase activity in basal cell carcinomas and in tumour-free surgical margins. Int J Oncol. 2003 Nov;23(5):1389-99.
262. Burnworth B, Arendt S, Muffler S, Steinkraus V, Brocker EB, Birek C, et al. The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1. Eur. J. Cell Biol. 2007 Dec;86(11-12):763-80.
263. Saleh S, King-Yin Lam A, Gertraud Buettner P, Glasby M, Raasch B, Ho YH. Telomerase activity of basal cell carcinoma in patients living in North Queensland, Australia. Hum. Pathol. 2007 Jul;38(7):1023-9.
264. Fabricius EM, Kruse-Boitschenko U, Khoury R, Wildner GP, Raguse JD, Klein M, et al. Localization of telomerase hTERT protein in frozen sections of basal cell carcinomas (BCC) and tumor margin tissues. Int. J. Oncol. 2009 Dec;35(6):1377-94.
265. Bonifas JM, Pennypacker S, Chuang PT, McMahon AP, Williams M, Rosenthal A, et al. Activation of expression of hedgehog target genes in basal cell carcinomas. J. Invest Dermatol. 2001 May;116(5):739-42.
266. Serewko MM, Popa C, Dahler AL, Smith L, Strutton GM, Coman W, et al. Alterations in gene expression and activity during squamous cell carcinoma development. Cancer Res. 2002 Jul 1;62(13):3759-65.
267. Smith AP, Weeraratna AT, Spears JR, Meltzer PS, Becker D. SAGE identification and fluorescence imaging analysis of genes and transcripts in melanomas and precursor lesions. Cancer Biol Ther. 2004 Jan;3(1):104-9.
268. Smith AP, Hoek K, Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther. 2005 Sep;4(9):1018-29.
269. Howell BG, Solish N, Lu C, Watanabe H, Mamelak AJ, Freed I, et al. Microarray profiles of human basal cell carcinoma: insights into tumor growth and behavior. J. Dermatol Sci. 2005 Jul;39(1):39-51.
270. Nindl I, Dang C, Forschner T, Kuban RJ, Meyer T, Sterry W, et al. Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling. Mol. Cancer. 2006;5:30.
271. O'Driscoll L, McMorrow J, Doolan P, McKiernan E, Mehta JP, Ryan E, et al. Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays. Mol. Cancer. 2006;5:74.
272. Dang C, Gottschling M, Manning K, O'Currain E, Schneider S, Sterry W, et al. Identification of dysregulated genes in cutaneous squamous cell carcinoma. Oncol. Rep. 2006 Sep;16(3):513-9.
273. Asplund A, Gry Bjorklund M, Sundquist C, Stromberg S, Edlund K, Ostman A, et al. Expression profiling of microdissected cell populations selected from basal cells in normal epidermis and basal cell carcinoma. Br. J. Dermatol. 2008 Mar;158(3):527-38.
274. Yu M, Zloty D, Cowan B, Shapiro J, Haegert A, Bell RH, et al. Superficial, nodular, and morpheiform basal-cell carcinomas exhibit distinct gene expression profiles. J. Invest Dermatol. 2008 Jul;128(7):1797-805.
275. Carlson JA, Linette GP, Aplin A, Ng B, Slominski A. Melanocyte receptors: clinical implications and therapeutic relevance. Dermatol Clin. 2007 Oct;25(4):541-57, viii-ix.
276. Ge L, Meng W, Zhou H, Bhowmick N. Could stroma contribute to field cancerization? Med. Hypotheses. 2010 Feb 8.
277. Carlson JA, Mu XC, Slominski A, Weismann K, Crowson AN, Malfetano J, et al. Melanocytic proliferations associated with lichen sclerosus. Arch. Dermatol. 2002 Jan;138(1):77-87.
278. Wright TI, Spencer JM, Flowers FP. Chemoprevention of nonmelanoma skin cancer. J. Am. Acad. Dermatol. 2006 Jun;54(6):933-46; quiz 47-50.
279. Otley CC, Stasko T, Tope WD, Lebwohl M. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg. 2006 Apr;32(4):562-8.
280. Einspahr JG, Stratton SP, Bowden GT, Alberts DS. Chemoprevention of human skin cancer. Crit. Rev. Oncol. Hematol. 2002 Mar;41(3):269-85.
281. Slominski A, Tobin DJ, Zmijewski MA, Wortsman J, Paus R. Melatonin in the skin: synthesis, metabolism and functions. Trends Endocrinol. Metabol.:. 2008 Jan-Feb;19(1):17-24.
282. Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. Faseb J. 2005 Feb;19(2):176-94.
283. Bikle DD, Oda Y, Xie Z. Vitamin D and skin cancer: a problem in gene regulation. The J Steroid Biochem Molec Biol. 2005 Oct;97(1-2):83-91.
284. Slominski A. Are suberythemal doses of ultraviolet B good for your skin? Pigment Cell Melanoma Res. 2009 Apr;22(2):154-5.
285. Slominski AT, Janjetovic Z, Fuller BE, Zmijewski MA, Tuckey RC, Nguyen MN, et al. Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity. PLoS One. 2010;5(3):e9907.
286. Bikle DD. Vitamin D receptor, UVR, and skin cancer: a potential protective mechanism. J. Invest Dermatol. 2008 Oct;128(10):2357-61.
287. Zmijewski MA, Slominski AT. CRF1 receptor splicing in epidermal keratinocytes: potential biological role and environmental regulations. J. Cell Physiol. 2009 Mar;218(3):593-602.
288. Slominski A, Zbytek B, Zmijewski M, Slominski RM, Kauser S, Wortsman J, et al. Corticotropin releasing hormone and the skin. Front Biosci. 2006;11:2230-48.
289. Slominski A, Wortsman J, Pisarchik A, Zbytek B, Linton EA, Mazurkiewicz JE, et al. Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. FASEB J. 2001 Aug;15(10):1678-93.
290. Ren ZP, Ponten F, Nister M, Ponten J. Two distinct p53 immunohistochemical patterns in human squamous-cell skin cancer, precursors and normal epidermis. Int. J. Cancer. 1996 Jun 21;69(3):174-9.
291. Turner ML. Sun, drugs, and skin cancer: a continuing saga. Arch. Dermatol. 2010 Mar;146(3):329-31.
292. Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis -an update. Br. J. Dermatol. 2007 Dec;157 Suppl 2:18-20.
293. Durham SE, Krishnan KJ, Betts J, Birch-Machin MA. Mitochondrial DNA damage in non-melanoma skin cancer. Br. J. Cancer. 2003 Jan 13;88(1):90-5.
294. Berneburg M, Gattermann N, Stege H, Grewe M, Vogelsang K, Ruzicka T, et al. Chronically ultraviolet-exposed human skin shows a higher mutation frequency of mitochondrial DNA as compared to unexposed skin and the hematopoietic system. Photochem. Photobiol. 1997 Aug;66(2):271-5.
295. Ren ZP, Hedrum A, Ponten F, Nister M, Ahmadian A, Lundeberg J, et al. Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes. Oncogene. 1996 Feb 15;12(4):765-73.
296. Rolfe KJ, Crow JC, Benjamin E, Reid WM, Maclean AB, Perrett CW. Cyclin D1 and retinoblastoma protein in vulvar cancer and adjacent lesions. Int. J. Gynecol Cancer. 2001 Sep-Oct;11(5):381-6.